Elekta (OTCMKTS:EKTAY – Get Free Report) and SiBone (NASDAQ:SIBN – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, dividends, risk and institutional ownership.
Insider and Institutional Ownership
98.1% of SiBone shares are held by institutional investors. 41.3% of Elekta shares are held by company insiders. Comparatively, 4.0% of SiBone shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Risk and Volatility
Elekta has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, SiBone has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500.
Profitability
This table compares Elekta and SiBone’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Elekta | -2.38% | 13.47% | 3.84% |
| SiBone | -6.85% | -8.23% | -6.07% |
Valuation and Earnings
This table compares Elekta and SiBone”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Elekta | $1.78 billion | 1.22 | -$55.38 million | ($0.12) | -49.25 |
| SiBone | $200.93 million | 4.95 | -$18.90 million | ($0.34) | -65.91 |
SiBone has lower revenue, but higher earnings than Elekta. SiBone is trading at a lower price-to-earnings ratio than Elekta, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current ratings for Elekta and SiBone, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Elekta | 0 | 1 | 0 | 0 | 2.00 |
| SiBone | 1 | 0 | 6 | 0 | 2.71 |
SiBone has a consensus target price of $24.50, suggesting a potential upside of 9.33%. Given SiBone’s stronger consensus rating and higher probable upside, analysts clearly believe SiBone is more favorable than Elekta.
Summary
Elekta beats SiBone on 8 of the 14 factors compared between the two stocks.
About Elekta
-logo-1200x675.png?v=20240604134456){kind=logo}
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services. It also provides Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Geneva, an applicator for cervical cancer treatment; veterinary radiation therapy products; and Elekta Kaiku for personalized cancer care. In addition, the company offers stereotactic radiosurgery, such as Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Elekta Esprit. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.
About SiBone
SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
Receive News & Ratings for Elekta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elekta and related companies with MarketBeat.com's FREE daily email newsletter.
